Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancer.

Familial cancer - 22 Jul 2026

Kell Emma A, Mullane Michael P, Geurts Jennifer L, Ramczyk Brenda, Bachinski Tessa M

Abstract excerpt

In 2023, the National Comprehensive Cancer Network® (NCCN®) updated its guidelines for managing breast cancer risk in patients with a CHEK2 p.I157T variant, recommending de-escalation of enhanced screening based on this variant alone. This shift reflects evidence that some missense variants carry a lower cancer risk than CHEK2 loss-of-function variants. A reduced cancer risk is particularly well established for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Communication

Share to Genetic Counseling

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Heterozygote

Share to Practice Guidelines as Topic

Source

Identifiers

PMID: 42484929
DOI: 10.1007/s10689-026-00590-z

Genes

CHEK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancer.PMID 42484929Read ↗

Impact of Updated NCCN Guidelines on Clinical Management and Risk Communication for CHEK2 p.I157T Carriers in Breast CancerSemantic proximity Read ↗

Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants.Semantic proximity Read ↗

CHEK2-related breast cancer: real-world challenges.Semantic proximity Read ↗

Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer.Semantic proximity Read ↗

An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on ATM and CHEK2.Semantic proximity Read ↗

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.Semantic proximity Read ↗

Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative.Semantic proximity Read ↗

An overview of genetic services delivery for hereditary breast cancer.Semantic proximity Read ↗

Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.